is the most common chromosomal translocation in acute myeloid leukemia (AML) in both children and adults. We sought to understand the structure and gain insight into the fusion process between AML1 and ETO by sequencing genomic fusions in 17 primary childhood AMLs and two cell lines with t(8;21). Reciprocal translocations were sequenced for seven of the 19 samples. We assumed a null hypothesis that the translocation breakpoints would be evenly distributed along the intronic breakpoint cluster regions. Testing for multimodality via smoothed bootstrap statistical methods suggested, however, the presence of two separate cluster regions within both the AML1 and ETO breakpoint cluster regions. ETO breakpoints were predominantly located in intron 1B in a defined cluster 5Ј of exon 1A (scan statistic P value = 0.00001). All patients with available RNA expressed an AML1-ETO mRNA fusion between exon 5 of AML1 and exon 2 of ETO. Since the structural restraints for the fusion protein of AML1-ETO exclude exon 1A, we reason that ETO intron 1B harbors a structural feature with propensity for breakage and/or recombination. Chromosomal breakpoints displayed evidence of fusion by a non-homologous end joining process, with microhomologies and nontemplate nucleotides at some fusion junctions. Breakpoints in general displayed similar complexity of duplications, deletions, and insertions to other common pediatric leukemia translocations (TEL-AML1, MLL-AF4, PML-RARA, CBFB-MYH11) that we and others have analyzed. Leukemia (2001Leukemia ( ) 15, 1906Leukemia ( -1913 
Introduction
Chromosomal translocations resulting in specific fusion genes are a hallmark of the leukemias. While studies of the fusion proteins have yielded extensive information on the biology and clinicopathology of the leukemias, less is understood about the structure and etiology of chromosomal fusions themselves. Genomic mapping and sequencing of chromosomal fusion junctions of specific types has led to speculations on the possible mechanisms of formation of these fusion junctions. The most explicit causal mechanism appears to be the aberrant involvement of the V(D)J recombinase RAG genes in the formation of chromosomal fusions of TCR and IG genes with various oncogenes, and occasionally between introns of genes not involved in TCR or IG rearrangement in the lymphomas and some leukemias (eg . Clinical and molecular reports have implicated multiagent chemotherapy including topoisomerase II-inhibiting drugs as a putative cause of several leukemia translocation types, including MLL rearrangements, NUP98-EOS and various fusions involving AML1. [6] [7] [8] [9] [10] [11] [12] Progress in characterizing the majority of leukemia translocations has been slower due to dispersed nature of the chromosomal fusions and difficulties in sequencing translocations because of large intronic regions; however, large-scale sequencing efforts have recently been undertaken. [13] [14] [15] [16] [17] The only pediatric translocation to date with hypothesized etiologies are the MLL fusions in infant leukemia, in which topoisomerase II inhibition by environmental and dietary agents may play a role. [18] [19] [20] The most common rearrangement in childhood leukemias is t(12;21)TEL-AML1, and we and others have noted structural features of the introns that may contribute to genomic breakage and refusion, including unstable repeat sequences and signs of non-homologous end joining repair.
14, [21] [22] [23] [24] T(8;21) (AML1-ETO) is a common recurrent translocation (ෂ12% overall) in both childhood and adult AML. This translocation is primarily a de novo, or idiopathic event, by the lack of identified causal exposure in most of the cases. T (8;21) occasionally occurs in leukemias associated with prior exposure to cancer chemotherapy of both alkylator and topoisomerase II inhibitor activity, 8, [25] [26] [27] [28] [29] and has also been reported in leukemias associated with certain occupational exposures. [30] [31] [32] [33] AML1 is occasionally fused to other partners in therapy-related leukemias, including EVI-1/MDS/EAP, MTG16, and other partners in chromosomes 1, 12, 14 and others.
9,34,35 AML1-ETO fusion produces a chimeric oncoprotein consisting of the runt-homology domain of AML1 on chromosome 21 fused to nearly the entire gene of ETO on chromosome 8. AML1 and ETO are both involved in transcriptional regulation of genes in hematopoietic precursor cells (reviewed in Ref. 36) .
In an effort to explore the nature of de novo AML1-ETO translocations, we sequenced the genomic fusion between chromosomes 8 and 21 in a series of 17 primary childhood leukemias and two cell lines that were derived from adult leukemias. AML1-ETO fusions were previously demonstrated by Tighe and Calabi, using Southern blotting, to predominantly harbor breakpoints in intron 1B of ETO. 37, 38 Using genomic sequencing and two complementary statistical approaches we confirmed and further demarcated this particular feature as well as demonstrating evidence of clustering of AML1 breakpoints. We also note other features indicating a complex breakage-refusion process that is consistent with the 'damagerepair' model of chromosomal translocation.
Materials and methods

Patients and cell lines
Patients were derived from two case-control epidemiology studies of childhood leukemia, the UK Childhood Cancer Study and the Northern California Childhood Leukemia Study. These are population-based epidemiology studies and therefore we anticipate no bias in patient selection that would influence breakpoint characteristics. Biological samples were obtained before treatment, by consent, and consisted of either blood or bone marrow. T(8;21) translocations were identified in diagnostic karyotypes. For some patients, RNA was isolated from mononuclear blast cells (purified by Ficoll density-differential centrifugation), using phenol-guanidium isothiocyanate procedures. Expression of AML1-ETO was confirmed by reverse transcription-PCR (RT-PCR) using standard primers and techniques. 39 High molecular weight DNA was isolated using conventional SDS-proteinase K digestion DNA isolation methods. All studies were reviewed and passed by the Institutional Review Boards at the institutions of the authors, and at all of the hospitals where patient material was derived.
The Kasumi 40 and SKNO-1 41 cell lines were kindly provided by N Kamada (Research Institute for Nuclear Medicine and Biology, Hiroshima, Japan) and S Matozaki (Hyogo Medical Center for Adults, Japan), respectively. DNA and RNA were isolated as above. A final patient sample previously sequenced was included in the clustering analysis. 42 
Sequencing of genomic fusion of AML1-ETO
Genomic fusions of AML1 intron 5 and ETO intron 1 or 2 were performed by long distance inverse PCR (LDI-PCR) especially when DNA was limiting, and by conventional long distance PCR techniques. Since the AML1 genomic breakpoint region is smaller than ETO, the AML1 region was used as the anchor for LDI-PCR. BamH1 digestion yields two large fragments of this region, allowing for four sets of inverse primers ( Figure 1 ). Inverse PCR was performed exactly as described, 22 but using only a single enzyme, BamH1, which creates two fragments from AML1 exon 5. This allowed for four primer sets to identify the AML1-ETO fusion (AMLinv1 and AMLinv3 M each deoxynucleotidyl transferase (dNTP), and 0.5 l Elongase enzyme (Life Technologies, Carlsbad, CA, USA) in a 50 l reaction was subjected to 35 cycles (94°C for 1 min, 60°C for 1 min, and 72°C for 1 min) followed by an extension at 72°C for 7 min. PCR products were checked on agarose gels.
For conventional LD-PCR, nine primers at approximately 6 kb intervals were designed for ETO, and four primers for AML1 (Figure 1 ). To limit the number of reactions, two AML1 primers (AML 6 and 18 in one reaction, and 12 and 24 in the other) were combined with each ETO primer, to allow for a total of 18 reactions for each patient. The three primers (6 pmoles each) were combined in a PCR reaction with 200 ng DNA with Elongase enzyme (Life Technologies) and the same reaction conditions as described above. PCR cycling for all LDI and LD reactions consisted of 40 cycles of 92°C, 30 s, 68°C, 20 min.
Amplification bands with suspected rearrangements (based on size) were excised from agarose gels, cleaned (Qiagen Gel Purification Kit, Valencia, CA, USA), and sequenced using the same primers as were used in the PCR reaction. Upon confirming the presence of AML1 and ETO sequence at the distal ends of the PCR product, additional PCR primers were synthesized at 1 kb intervals on the AML1 gene only. An additional round of PCR with the single ETO primer (or the AML1 inverse PCR primer proximal to the BamH1 site) and each new 1 kb interval AML1 primer was used to narrow down the location of the breakpoint. Usually, only one additional sequencing reaction with the AML1 primer most proximal to the breakpoint revealed the breakpoint sequence.
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Statistical analysis
Using GenBank-derived genomic sequence, maps of breakpoint locations were constructed. Clustering of breakpoints was assessed using both Silverman's (1981) smoothed bootstrap procedure and scan statistic approximations, these being either large deviation 43 or moment 44 based. The approaches are complementary in that the smoothed bootstrap procedure provides a formal test for the number of clusters (equivalently modes) that is global (ie dependent on all the data) in nature, whereas the scan statistic is tuned to assessing the significance of a target (local) cluster and is unaffected by the data density/sparsity outside that target. Detailed description of methods are presented elsewhere. 45 Silverman's smoothed bootstrap procedure uses (Gaussian) kernel density estimation. A critical bandwidth is defined such that any decrease in this bandwidth results in the corresponding density estimate gaining a mode. The density estimate associated with the critical bandwidth is called the critical density. Smoothed bootstrap resampling from this critical density is then performed a large number of times. For each replicate sample, a kernel density estimate, using the critical bandwidth, is constructed and the number of modes determined. The proportion of times this number exceeds the number of modes in the critical density gives the P value for whether an additional mode is required.
The scan statistic is based on the maximal number of breakpoints occurring within an interval of prescribed length. The scan statistic null distribution is based on the maximum number of breakpoints in the interval assuming a uniform breakpoint density, this reflecting an absence of clustering. Again, a detailed description of this methodology is presented elsewhere. 45 
Results
All of the 19 available patient samples and cell lines were successfully sequenced for AML1-ETO using the combined approaches of LD-and LDI-PCR (six were sequenced by both approaches). One breakpoint (patient 3) mapped to chromosome 11 rather than chromosome 8, indicating that this breakpoint may be a three-way translocation. For seven patients, amplification of the reciprocal ETO-AML1 by inverse PCR (using the inv 2A/B or inv 4A/B combinations, see Figure 1 ) were successful. For the remainder, breakpoints of the reciprocal may have been outside of the introns targeted, or simply yielded PCR products out of the practical range of the inverse PCR assay.
Of the 19 total patients and cell lines available, RNA was obtained from nine. RT-PCR analysis of these nine revealed a single band indicating a fusion between exon 5 of AML1 and exon 2 of ETO. It was therefore intriguing that 13 of the 19 breakpoints, plus one additional previously sequenced AML1-ETO fusion, 42 were positioned prior to an alternative exon 1 of ETO (exon 1A) which was not found in any mRNAs tested (Figure 2) , confirming an earlier observation using Southern blotting. 37, 38 mRNA sequences of all patients tested were indistinguishable with regards to mRNA sequence to Kasumi and SKNO-1 cell lines, which both had breakpoints within intron 2 of ETO (Figure 2) .
AML1-ETO fusions displayed a high degree of complexity proximal to the breakpoint; a similar or higher complexity than another breakpoint that we have analyzed extensively, TEL-AML1. For example, seven of 27 (26%) AML1-ETO fusions displayed nontemplate N-nucleotides, and another 14 (52%) displayed microhomologies at breakpoints (Table 1) . Only six (22%) lacked either feature. TEL-AML1 fusions that we have sequenced (data from Refs 14 and 22) demonstrated N-nucleotides in only 1/27 breakpoints (4%), but a similar rate of microhomologies, at 14 of 27, (52%). Of the seven breakpoints in which AML1-ETO and its reciprocal were sequenced, deletions of 5 to 18 099 bp were present in eight of 14 breakpoints and duplications of 1 to 1512 bp were apparent in the other six breakpoints (Table 2) . These large and variable additions/deletions of DNA indicate that the translocations were not exactly reciprocal, but that DNA at the proximal ends of breakpoints was extensively processed prior to fusion. A single fusion (breakpoint No. 18) demonstrated an internal tandem duplication on the same derivative chromosome (Figure 3) , a feature not previously observed in TEL-AML1 translocations. Despite the presence of nontemplate nucleotides in seven breakpoints, other features of V(D)J recombination were absent from breakpoints, including consensus heptamer-nonamer RSS sequences or strong clustering around cryptic RSS sequences. In addition, the duplications present in reciprocal translocations are not compatible with typical V(D)J-mediated recombination mechanisms (Figure 4) .
A statistical test of clustering, the scan statistic, was applied to both AML1 and ETO genomic regions for the 20 total breakpoints. Scan statistics are based on the number of events occurring within a window along the intronic sequence. A marginally significant cluster was apparent on the 3Ј end of AML1 exon 5 (P = 0.09, right mode on Figure 5a ). The 3Ј region of AML1 did not harbor a significant cluster (P = 0.83, left mode, Figure 5a) . ETO, on the other hand, demonstrated a highly significant cluster (P = 0.00001) 5Ј to exon 1A ( Figure  2a and 5b). This held true even when evaluating significance without using prescribed interval lengths. To evaluate the overall clumping of breakpoints in the region, we applied a bandwidth test with significance evaluation by smoothed bootstrap after Silverman. 46 This procedure is more global in nature than the scan statistic, and is used to assess the number of modes, or bumps, in the breakpoint density. This procedure rejected the null hypothesis of a single cluster for both AML1 (P Ͻ 0.0001 at a critical bandwidth of 27 826 bp) and ETO (P = 0.001 at a critical bandwidth of 47 078 bp) but did not reject a null of two clusters (null hypothesis for two clusters for AML1, P = 0.73 at a bandwidth of 6013; ETO, P = 0.31 at a bandwidth of 14 420). The data then suggest the existence of two modes on each gene as depicted in Figure 5 . This is an indication of overall clumping, or clustering, of the breakpoints, but not a formal assessment of the significance of individual clusters as provided by the scan statistic.
Discussion
AML constitutes about 20% of all childhood leukemias, and t(8;21) occurs in 12-20% of these cases. While t(8;21) is generally a marker of a more favorable prognosis in adults, this is not true for children, with only a 30% long-term remission rate. [47] [48] [49] Ultimately, prevention of this and other leukemia subtypes is a goal, one that can only be reached by better understanding the disease's causes.
Apart from infant leukemias with MLL translocations, there are no known and few hypothesized etiologies for childhood acute myeloid leukemia (AML). In the current report, we describe methods to rapidly sequence and analyze t(8;21) fusions in children for the purpose of addressing the question of what caused this fusion. These data, when combined with large-scale epidemiology studies of childhood leukemia and efforts to define the temporal origin of breakpoint fusions currently in progress, should ultimately result in a defined etiology of the disease and suggest preventative strategies.
We begin with the knowledge from clinical and functional studies that t(8;21) AML1-ETO constitutes a fusion protein between exon 5 of AML1 and exon 2 of ETO. Functional studies have implicated that both the AML1 and ETO protein subunits are necessary for the oncogenic function of the chimeric gene, 50, 51 despite reports of the occurrence of alternative spliced mRNAs which are present at much lower relative quantity to the AML1 exon 5-ETO exon 2 fusion in leukemic blasts. 38, 52, 53 These studies of aberrant transcripts have all utilized non-quantitative nested PCR or PCR-Southern blotting to Leukemia detect such transcripts, and do not indicate their relative abundance to the AML1 exon 5-ETO exon 2 transcript. Seven of our patient samples with available RNA and two cell lines expressed the common transcript exclusively after a single round of PCR. We previously found in a screen of 40 patients that the AML1 exon 5-ETO exon 2 fusion was the exclusive detectable product after a single round of PCR followed by Southern blotting and hybridization of the product. 54 Additional work on the pathophysiologic relevance of the fusion protein has indicated that the ETO domain is necessary for the transcriptional alterations triggered by the fusion protein, making the contribution of aberrant out-of-frame transcripts uncertain. It is therefore peculiar that all but two of the childhood leukemia AML1-ETO fusions were within intron 1B of ETO, and furthermore that 12 of the breakpoints were Figure 3 for complete fusion structure. Key of patient numbers is in caption to Figure 2 . AML1 sequences are underlined, ETO are not. Microhomologies (nucleotides at the breakpoint that are the same on both AML1 and ETO) are noted in bold, and non-template sequences in lower case letters. Locations of breakpoints are referenced to locations in GenBank sequences. located within a range of 3245 bp, resulting in highly significant clustering by statistical analysis (Results and Figure 5b ). This clustering, as well as evidence of clumping of breakpoints at the 5Ј and 3Ј ends of AML1 intron 5, could indicate regions of DNA or chromatin structure particularly susceptible to recombination in comparison to the surrounding sequence. The lack of specific recombination site sequences or DNA interspersed repeats in proximity to the breakpoints argues against the presence of 'hotspots' such as V(D)J recombinase site sequences. This complexity of the breakpoints is shared by MLL-AF4, TEL-AML1, PML-RARA, and CBFB-MYH11, translocations which occur in pediatric ALL as well as AML. [14] [15] [16] 22, [55] [56] [57] These translocations like AML-ETO in children are not associated with etiologic causal agents in the vast
Figure 4
Schematic diagrams indicate duplications (striped boxes) and deletions (hollow boxes), and demonstrate pictorially the relationship between the der 8 (AML1-ETO), der 21 (ETO-AML1) and the parent chromosomes containing AML1 and ETO. We represent only two patients, as an example, in which information regarding both reciprocals is known, information about the other five are in Table 2 majority of cases. TEL-AML1 is known to occur in utero in most patients tested, [58] [59] [60] and the temporal origin of AML1-ETO in childhood leukemia is currently under scrutiny. Future studies on AML1-ETO breakpoint etiology will benefit from a comparison of the de novo children's breakpoints described in the current report with those in adult and therapy-related leukemias.
Several etiologies of the adult AMLs are well defined, most notable, AML resulting from prior multiagent chemotherapy regimens, radiation, and benzene. T(8;21) is a common translocation in the AML subclass FAB-M2 (ෂ40%), and has been associated with benzene exposure. 61 Translocation(8;21) is also an occasional cytogenetic abnormality in therapy-related leukemias, and has in particular been associated with exposure to the topoisomerase II inhibitor, doxorubicin. 8, 29 In this context, the marginally significant cluster at the 3Ј end of AML1 (P = 0.09, Figure 5a ) is worthy of notice in light of a strong in vivo topoisomerase II site found in this area by Stanulla and colleagues, 62 who used topoisomerase II-inhibiting drug-treated cultured cell lines in defining this hypersensitive region. A near-consensus topoisomerase II site was also found in DNA sequence analysis, 62 and one of our childhood t(8;21) breakpoints (No. 18) was found to be located 30 bp from this site, with nine of the 20 breakpoints forming a cluster to the 5Ј end of the site. The potential significance of this association is unknown, as we emphasize that pediatric AML with t(8; 21) has not been associated with exogenous chemical exposures
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Figure 5
Silverman smoothed bootstrap for the determination of the numbers of cluster 'modes'. The curves are drawn according to breakpoint density, and smoothing based on bootstrap resampling (see Methods). Breakpoint density maps visually suggest two or three cluster modes for both AML1 and ETO. The corresponding statistic for both regions rejects the null hypothesis of one single cluster, but fails to reject, in a separate test, the null hypothesis of two clusters (see Results), thus providing evidence for two separate cluster regions within both (a) AML1 and (b) ETO introns.
in any studies to date. The sequencing of additional patient breakpoints, in particular those from adults with occupational exposures or prior exposure to chemotherapy, will provide more information about the relevance of this feature.
A final interesting feature of t(8;21) is the presence of nontemplate nucleotides at a significant number of the breakpoints. These nucleotides were present at a higher rate (7/25, 28%) than that which we previously observed for TEL-AML1 breakpoints in children (1/27, 4%, see Results). It should be noted that others have observed a higher rate of N-nucleotides in TEL-AML1, being present in three of six breakpoints, or 50%. 21 The presence of non-template nucleotides is suggestive of the activity of the enzyme terminal deoxynucleotidyl transferase (TdT) which is normally a lymphocyte-specific enzyme, and would not be expected for a myeloid-origin leukemia such as t (8;21) + AML. Non-template nucleotides can arise from other sources, such as fragments of deletions as has been suggested for MLL-AF4, 56 or templated short patch DNA synthesis as suggested for IGH-BCL2. 2 Given the very short nature of the non-template nucleotides present here (1-4 nucleotides) we are currently unable to trace the origin of these nucleotides.
While the human genome project is essentially finished, techniques such as inverse PCR or panhandle PCR might be thought to be supplanted by conventional long-distance PCR for genomic applications such as breakpoint sequencing. However, in our experience, inverse PCR is highly useful for samples in which DNA is limiting, or cases in which genomic breakpoint cluster regions are of vastly different sizes on partner chromosomes. In the latter case, inverse or panhandle PCR techniques can use the smaller breakpoint cluster region as the anchor, the larger region as the target. We continue to refine the molecular biologic and statistical methodology to characterize these breakpoint regions in the leukemias, and will incorporate these techniques into traditional large-scale epidemiology studies of leukemia to better understand the etiology and natural history of leukemia.
